Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurie Markman

Showing results (81-90 of 413) with videos related to

Pageof 42
Sort By:
Oncology|July 25, 2007
Efforts to define a role for recombinant erythropoietin in cancer managementMaurie Markman
Gynecologic Oncology|July 31, 2007
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trialsMaurie Markman
Cancer|September 20, 2007
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of cautionMaurie Markman
Archives of Internal Medicine|July 26, 2006
"Therapeutic intent" in phase 1 oncology trials: a justifiable objectiveMaurie Markman
Gynecologic Oncology|May 29, 2007
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancerMaurie Markman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2007
Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for actionMaurie Markman
Gynecologic Oncology|February 13, 2010
"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer"Maurie Markman
Gynecologic Oncology|February 20, 2010
"Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?Maurie Markman
Gynecologic Oncology|July 25, 2018
Response to: "Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomastis (Chua TC, et al.)"Maurie Markman
Cancer Investigation|December 27, 2005
Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practiceMaurie Markman
Pageof 42

Showing results (81-90 of 413) with videos related to

Sort By:
Pageof 42
Oncology|July 25, 2007
Efforts to define a role for recombinant erythropoietin in cancer managementMaurie Markman
Gynecologic Oncology|July 31, 2007
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trialsMaurie Markman
Cancer|September 20, 2007
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of cautionMaurie Markman
Archives of Internal Medicine|July 26, 2006
"Therapeutic intent" in phase 1 oncology trials: a justifiable objectiveMaurie Markman
Gynecologic Oncology|May 29, 2007
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancerMaurie Markman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2007
Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for actionMaurie Markman
Gynecologic Oncology|February 13, 2010
"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer"Maurie Markman
Gynecologic Oncology|February 20, 2010
"Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?Maurie Markman
Gynecologic Oncology|July 25, 2018
Response to: "Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomastis (Chua TC, et al.)"Maurie Markman
Cancer Investigation|December 27, 2005
Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practiceMaurie Markman
Pageof 42